Scientific Reports · 2018 · 46 citations · 25 references
MedicineMedicinal ChemistryPharmacologyAutoimmunityDrug DiscoveryRheumatologyAutoimmune Rheumatic DiseasesInflammatory ArthritisRheumatoid ArthritisTyrosine Kinase InhibitorsCell-based AssaysCollagen-induced ArthritisCysteine ConjugationJak InhibitorsKinase InhibitorsLiquid Chromatography-mass SpectrometryLiquid Chromatography-mass Spectrometry AnalysisRheumatoid Arthritis Therapy
Abstract Janus tyrosine kinase 3 (JAK3) is expressed in lymphoid cells and is involved in the signalling of T cell functions. The development of a selective JAK3 inhibitor has been shown to have a potential benefit in the treatment of autoimmune disorders. In this article, we developed the 4-aminopiperidine-based compound RB1 , which was highly selective for JAK3 inhibition, with an IC 50 of value of 40 nM, but did not inhibit JAK1, JAK2 or tyrosine kinase 2 (TYK2) at concentrations up to 5 µM. Furthermore, RB1 also exhibited favourable selectivity against a panel of representative kinases. In a battery of cytokine-stimulated cell-based assays, this potent inhibitor of JAK3 activity with good selectivity against other kinases could potently inhibit JAK3 activity over the activity of JAK1 or JAK2 (over at least 100-fold). A combination of liquid chromatography-mass spectrometry (LC-MS) experiments validated that RB1 covalently modified the unique cysteine 909 residue in JAK3. In vivo , RB1 exerted significantly improved pathology in the joints of a collagen-induced arthritis mouse model. The reasonable pharmacokinetics properties (F = 72.52%, T1/2 = 14.6 h) and favourable results of toxicology experiments (LD 50 > 2 g/kg) suggest that RB1 has the potential to be an efficacious treatment for RA.
25
Prevention of Organ Allograft Rejection by a Specific Janus Kinase 3 Inhibitor
Paul S. Changelian, Mark E. Flanagan, Douglas J. Ball et al. · Science · 2003 · 670 citations · Full text
Medicine, Immunology, Pharmacology +17
Interleukin 6 Is Required for the Development of Collagen-induced Arthritis
Tonino Alonzi, Elena Fattori, Domenico Lazzaro et al. · The Journal of Experimental Medicine · 1998 · 609 citations · Full text
Medicine, Immunology, Pathobiology +16
Functional Activation of Jak1 and Jak3 by Selective Association with IL-2 Receptor Subunits
Tadaaki Miyazaki, Atsuo Kawahara, Hodaka Fujii et al. · Science · 1994 · 594 citations
Mark E. Flanagan, J. A. Abramite, Dennis P. Anderson et al. · Journal of Medicinal Chemistry · 2014 · 324 citations